Skip to main content
. 2024 Jan 17;67(2):1225–1242. doi: 10.1021/acs.jmedchem.3c01714

Figure 4.

Figure 4

Compounds 30–33 and identification of clinical compounds BAY1830839 and BAY1834845, starting from compound 30 based on key selectivity data and PK data from in vivo studies in rats. Biochemical potency data for IRAK4 inhibition (1 mM ATP) and FLT3 inhibition (10 μM ATP) are also shown.